Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences

被引:24
|
作者
Noparatayaporn, Prapaporn [1 ,2 ]
Thavorncharoensap, Montarat [1 ,3 ]
Chaikledkaew, Usa [1 ,3 ]
Bagepally, Bhavani Shankara [4 ]
Thakkinstian, Ammarin [1 ,5 ]
机构
[1] Mahidol Univ Hlth Technol Assessment MUHTA Grad P, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Dept Pharm, Siriraj Hosp, Bangkok, Thailand
[3] Mahidol Univ, Social & Adm Pharm Div, Dept Pharm, Fac Pharm, 447 Sri Ayudhaya Rd, Bangkok 10400, Thailand
[4] ICMR Natl Inst Epidemiol, Chennai, Tamil Nadu, India
[5] Mahidol Univ, Fac Med, Dept Clin Epidemiol & Biostat, Ramathibodi Hosp, Bangkok, Thailand
基金
比尔及梅琳达.盖茨基金会;
关键词
Incremental net monetary benefit; Cost-effectiveness; Bariatric surgery; Economic evaluation;
D O I
10.1007/s11695-021-05415-9
中图分类号
R61 [外科手术学];
学科分类号
摘要
This systematic review aimed to comprehensively synthesize cost-effectiveness evidences of bariatric surgery by pooling incremental net monetary benefits (INB). Twenty-eight full economic evaluation studies comparing bariatric surgery with usual care were identified from five databases. In high-income countries (HICs), bariatric surgery was cost-effective among mixed obesity group (i.e., obesity with/without diabetes) over a 10-year time horizon (pooled INB = $53,063.69; 95% CI $42,647.96, $63,479.43) and lifetime horizon (pooled INB = $101,897.96; 95% CI $79,390.93, $124,404.99). All studies conducted among obese with diabetes reported that bariatric surgery was cost-effective. Also, the pooled INB for obesity with diabetes group over lifetime horizon in HICs was $80,826.28 (95% CI $32,500.75, $129,151.81). Nevertheless, no evidence is available in low- and middle-income countries.
引用
收藏
页码:3279 / 3290
页数:12
相关论文
共 50 条
  • [41] INCREMENTAL NET MONETARY BENEFIT OF DIRECT ORAL ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP REPLACEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Veettil, S. K.
    Harris, J.
    Syeed, M. S.
    Thakkinstian, A.
    Chaikledkaew, U.
    Witt, D. M.
    Chaiyakunapruk, N.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S389 - S389
  • [42] Effectiveness of exercise training after bariatric surgery-a systematic literature review and meta-analysis
    Bellicha, A.
    Ciangura, C.
    Poitou, C.
    Portero, P.
    Oppert, J. -M.
    [J]. OBESITY REVIEWS, 2018, 19 (11) : 1544 - 1556
  • [43] The Effectiveness and Risks of Bariatric Surgery An Updated Systematic Review and Meta-analysis, 2003-2012
    Chang, Su-Hsin
    Stoll, Carolyn R. T.
    Song, Jihyun
    Varela, J. Esteban
    Eagon, Christopher J.
    Colditz, Graham A.
    [J]. JAMA SURGERY, 2014, 149 (03) : 275 - 287
  • [44] The Effectiveness of Bariatric Surgery for Chinese Obesity in 2Years: A Meta-Analysis and Systematic Review
    Zeng, Tianshu
    Cai, Yuli
    Chen, Lulu
    [J]. JOURNAL OF INVESTIGATIVE SURGERY, 2017, 30 (05) : 332 - 341
  • [45] Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity
    Adnan Alsumali
    Tewodros Eguale
    Sigrid Bairdain
    Mihail Samnaliev
    [J]. Obesity Surgery, 2018, 28 : 2203 - 2214
  • [46] Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity
    Alsumali, Adnan
    Eguale, Tewodros
    Bairdain, Sigrid
    Samnaliev, Mihail
    [J]. OBESITY SURGERY, 2018, 28 (08) : 2203 - 2214
  • [47] Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost-utility studies
    Bagepally, Bhavani Shankara
    Kumar, S. Sajith
    Natarajan, Meenakumari
    Sasidharan, Akhil
    [J]. BMJ OPEN GASTROENTEROLOGY, 2022, 9 (01):
  • [48] One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
    Christopher McCabe
    Mike Paulden
    Isaac Awotwe
    Andrew Sutton
    Peter Hall
    [J]. PharmacoEconomics, 2020, 38 : 135 - 141
  • [49] One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
    McCabe, Christopher
    Paulden, Mike
    Awotwe, Isaac
    Sutton, Andrew
    Hall, Peter
    [J]. PHARMACOECONOMICS, 2020, 38 (02) : 135 - 141